Product Information
CLINDESSE 2% VAGINAL CREAM is a brand product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $26.6211 per GM under NDC 45802004201. Its NADAC has been published 537 times since Jul 29, 2015.
FDA first approved this application on Nov 30, 2004.
Strength
100 mg/5g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802004201
Classification
Brand
Dosage Form
CREAM
Route
VAGINAL
Effective Date
9/23/2026
Active Ingredients
CLINDAMYCIN PHOSPHATEApproval Type
New Drug (NDA)
FDA Application
NDA050793FDA Approved
11/30/2004
On Market Since
7/3/2015
Pharmacological Classes
Price Statistics
The NADAC for CLINDESSE 2% VAGINAL CREAM has been published 537 times since Jul 29, 2015, and over the history we have for it it has risen 84.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $26.6211 per GM |
|---|---|
| All-time high | $26.9624 (Apr 10, 2024) |
| All-time low | $14.4250 (Jul 29, 2015) |
| 52-week high | $26.7305 |
| 52-week low | $26.6183 |
| Median price | $24.2724 |
| Average price | $24.3371 |
| Largest weekly change | +33.0% (Apr 20, 2016) |
| Weeks tracked | 537 |
| Tracking since | Jul 29, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the clindamycin phosphate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
clindamycin phosphate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLINDESSE 2% VAGINAL CREAM?
The current National Average Drug Acquisition Cost (NADAC) for CLINDESSE 2% VAGINAL CREAM, manufactured by Padagis Israel Pharmaceuticals Ltd, is $26.6211 per GM (NDC 45802004201), effective Sep 30, 2026.
How has the price of CLINDESSE 2% VAGINAL CREAM changed over time?
Over the history we have for it, the NADAC for CLINDESSE 2% VAGINAL CREAM has risen 84.5%. It has been tracked across 537 weekly CMS publications since Jul 29, 2015.
What are the highest and lowest recorded NADAC prices for CLINDESSE 2% VAGINAL CREAM?
Since Jul 29, 2015, the NADAC for CLINDESSE 2% VAGINAL CREAM has ranged from a low of $14.4250 (Jul 29, 2015) to a high of $26.9624 (Apr 10, 2024), with a median of $24.2724 per GM.
Are there cheaper alternatives to CLINDESSE 2% VAGINAL CREAM?
No other NADAC-published product currently shares the active ingredient and strength of CLINDESSE 2% VAGINAL CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLINDESSE 2% VAGINAL CREAM?
CLINDESSE 2% VAGINAL CREAM (NDC 45802004201) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a brand product.